The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study - Concepedia

Concepedia

Publication | Open Access

The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study

DOI Full Paper Access

33

Citations

19

References

2012

Year

Isao Sakaida, M. Yanase, Yoshio Kobayashi, T Yasutake, Mitsuru Okada, K Okita, Fujito Kageyama, Hiroaki Miyaoka, Hiroki Nakamura, Hiroshi Sakaeda,

Journal of International Medical Research

Abstract

Tolvaptan at 3.75 mg/day exerts some effects due to the pharmacokinetic profile in patients with liver cirrhosis. Tolvaptan at 7.5 mg/day is a clinically useful option for treating patients who do not respond well to conventional diuretics.

References

	Year	Citations

Page 1